Drugs / Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)
Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)
also known as
cytotoxic T lymphocytes (CTLs)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02210065 | Mar 2015 → May 2019 | leukemia, lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02210065 ↗ |
| Known as | cytotoxic T lymphocytes (CTLs) | “The goal of this clinical research study is to learn if giving cytotoxic T lymphocytes (CTLs) can help control CMV when it reactivates (becomes active again) in patients who...” NCT02210065 ↗ |
| Modality | Cell therapy | “To create CTLs, blood cells are grown in the laboratory and trained to kill CMV.” NCT02210065 ↗ |
| Route | Intravenous | “you will receive the CTLs through a needle in your vein” NCT02210065 ↗ |